JP2023520392A - 間葉系幹細胞由来癌細胞および間葉系幹細胞関連疾患を標的とするイムノセラノスティック剤（ｉｍｍｕｎｏｔｈｅｒａｎｏｓｔｉｃ ａｇｅｎｔ） - Google Patents

間葉系幹細胞由来癌細胞および間葉系幹細胞関連疾患を標的とするイムノセラノスティック剤（ｉｍｍｕｎｏｔｈｅｒａｎｏｓｔｉｃ ａｇｅｎｔ） Download PDF

Info

Publication number
JP2023520392A
JP2023520392A JP2022559435A JP2022559435A JP2023520392A JP 2023520392 A JP2023520392 A JP 2023520392A JP 2022559435 A JP2022559435 A JP 2022559435A JP 2022559435 A JP2022559435 A JP 2022559435A JP 2023520392 A JP2023520392 A JP 2023520392A
Authority
JP
Japan
Prior art keywords
tumor
binding moiety
disease
lrrc15
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022559435A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021202642A5 (https=
JP2023520392A5 (https=
Inventor
ウルメルト，ハンス，デイヴィッド
ピークハウス，ノルバート
マオ，リカン
ダモワゾー，ロバート，ディー．
ストーリー，クレア
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of JP2023520392A publication Critical patent/JP2023520392A/ja
Publication of JPWO2021202642A5 publication Critical patent/JPWO2021202642A5/ja
Publication of JP2023520392A5 publication Critical patent/JP2023520392A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2022559435A 2020-04-01 2021-03-31 間葉系幹細胞由来癌細胞および間葉系幹細胞関連疾患を標的とするイムノセラノスティック剤（ｉｍｍｕｎｏｔｈｅｒａｎｏｓｔｉｃ ａｇｅｎｔ） Pending JP2023520392A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063003598P 2020-04-01 2020-04-01
US63/003,598 2020-04-01
PCT/US2021/025054 WO2021202642A2 (en) 2020-04-01 2021-03-31 Immunotheranostic agent targeting mesenchymal stem cell-derived cancer cells and mesenchymal stem cell associated disease

Publications (3)

Publication Number Publication Date
JP2023520392A true JP2023520392A (ja) 2023-05-17
JPWO2021202642A5 JPWO2021202642A5 (https=) 2024-04-10
JP2023520392A5 JP2023520392A5 (https=) 2024-04-10

Family

ID=77929889

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022559435A Pending JP2023520392A (ja) 2020-04-01 2021-03-31 間葉系幹細胞由来癌細胞および間葉系幹細胞関連疾患を標的とするイムノセラノスティック剤（ｉｍｍｕｎｏｔｈｅｒａｎｏｓｔｉｃ ａｇｅｎｔ）

Country Status (9)

Country Link
US (1) US20230133775A1 (https=)
EP (1) EP4125991A4 (https=)
JP (1) JP2023520392A (https=)
KR (1) KR20220161395A (https=)
CN (1) CN115379848A (https=)
AU (1) AU2021246485A1 (https=)
BR (1) BR112022019758A2 (https=)
CA (1) CA3174263A1 (https=)
WO (1) WO2021202642A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115975036B (zh) * 2022-08-18 2023-06-09 北京诺赛国际医学研究院 包含干细胞的药物组合物及其治疗癌症的用途
WO2024081729A2 (en) * 2022-10-12 2024-04-18 Mythic Therapeutics, Inc. Lrrc-15-binding protein constructs and uses thereof
TW202434310A (zh) * 2023-01-27 2024-09-01 日商第一三共股份有限公司 抗lrrc15抗體
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025076127A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025160129A1 (en) * 2024-01-23 2025-07-31 The Regents Of The University Of California Methods of use of agents targeting mesenchymal stem cell- derived tumors and tumor associated cells
WO2025179294A2 (en) 2024-02-22 2025-08-28 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025264059A1 (ko) * 2024-06-20 2025-12-26 주식회사 에디스바이오텍 Lrrc15에 특이적으로 결합하는 항체 및 이의 용도

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016056165A (ja) * 2014-08-12 2016-04-21 学校法人藤田学園 抗α６β４インテグリン抗体を利用したがん又は腫瘍の診断又は治療のための抗体製剤及び抗体キット
JP2018162306A (ja) * 2014-01-24 2018-10-18 デイナ ファーバー キャンサー インスティチュート，イ Ｐｄ−１に対する抗体分子およびその使用
JP2019500327A (ja) * 2015-11-30 2019-01-10 アッヴィ・インコーポレイテッド 抗ｈｕＬＲＲＣ１５抗体薬物コンジュゲート及びその使用方法
JP2019501124A (ja) * 2015-11-30 2019-01-17 アッヴィ・インコーポレイテッド 抗ｈｕＬＲＲＣ１５抗体薬物コンジュゲート及びその使用方法
WO2019195278A1 (en) * 2018-04-02 2019-10-10 Silverback Therapeutics, Inc. Alk5 inhibitors, conjugates, and uses thereof
WO2019203191A1 (ja) * 2018-04-16 2019-10-24 日本メジフィジックス株式会社 修飾抗体、および、放射性金属標識抗体

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9862770B2 (en) * 2005-10-19 2018-01-09 Ibc Pharmaceuticals, Inc. Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors
AR090549A1 (es) * 2012-03-30 2014-11-19 Genentech Inc Anticuerpos anti-lgr5 e inmunoconjugados
US10221242B2 (en) * 2016-01-21 2019-03-05 Pfizer Inc. Antibodies specific for epidermal growth factor receptor variant III and their uses
WO2018083087A2 (en) * 2016-11-02 2018-05-11 Glaxosmithkline Intellectual Property (No.2) Limited Binding proteins
EP3634485A4 (en) * 2017-06-07 2021-07-21 Silverback Therapeutics, Inc. CONJUGATES OF ANTIBODIES CONTAINING IMMUNOMODULATOR COMPOUNDS AND THEIR USES
TWI823906B (zh) * 2018-03-09 2023-12-01 美商艾吉納斯公司 抗-cd73 抗體及其使用方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018162306A (ja) * 2014-01-24 2018-10-18 デイナ ファーバー キャンサー インスティチュート，イ Ｐｄ−１に対する抗体分子およびその使用
JP2016056165A (ja) * 2014-08-12 2016-04-21 学校法人藤田学園 抗α６β４インテグリン抗体を利用したがん又は腫瘍の診断又は治療のための抗体製剤及び抗体キット
JP2019500327A (ja) * 2015-11-30 2019-01-10 アッヴィ・インコーポレイテッド 抗ｈｕＬＲＲＣ１５抗体薬物コンジュゲート及びその使用方法
JP2019501124A (ja) * 2015-11-30 2019-01-17 アッヴィ・インコーポレイテッド 抗ｈｕＬＲＲＣ１５抗体薬物コンジュゲート及びその使用方法
WO2019195278A1 (en) * 2018-04-02 2019-10-10 Silverback Therapeutics, Inc. Alk5 inhibitors, conjugates, and uses thereof
WO2019203191A1 (ja) * 2018-04-16 2019-10-24 日本メジフィジックス株式会社 修飾抗体、および、放射性金属標識抗体

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CANCERRES., vol. 78, no. 14, JPN6025018460, 2018, pages 4059 - 4072, ISSN: 0005807137 *
CANCERS, vol. 12, no. 3, JPN6025018461, 2020, pages 757, ISSN: 0005807138 *
JOURNALOF CLINICAL ONCOLOGY, vol. Vol. 37, No. 15_suppl, JPN6025018462, 2019, pages 3004, ISSN: 0005807139 *

Also Published As

Publication number Publication date
EP4125991A2 (en) 2023-02-08
WO2021202642A2 (en) 2021-10-07
KR20220161395A (ko) 2022-12-06
CA3174263A1 (en) 2021-10-07
US20230133775A1 (en) 2023-05-04
WO2021202642A3 (en) 2021-11-11
AU2021246485A1 (en) 2022-11-17
BR112022019758A2 (pt) 2023-01-31
EP4125991A4 (en) 2025-02-26
CN115379848A (zh) 2022-11-22

Similar Documents

Publication Publication Date Title
JP2023520392A (ja) 間葉系幹細胞由来癌細胞および間葉系幹細胞関連疾患を標的とするイムノセラノスティック剤（ｉｍｍｕｎｏｔｈｅｒａｎｏｓｔｉｃ ａｇｅｎｔ）
US12383637B2 (en) Therapeutic agents and uses thereof
JP7608425B2 (ja) 線維芽細胞活性化タンパク質リガンドを含む化合物およびその使用
Cheal et al. Theranostic pretargeted radioimmunotherapy of internalizing solid tumor antigens in human tumor xenografts in mice: Curative treatment of HER2-positive breast carcinoma
Wierstra et al. Tracers for non-invasive radionuclide imaging of immune checkpoint expression in cancer
WO2019177970A1 (en) Bispecific binding agents and uses thereof
US20240216554A1 (en) Radioimmunoconjugates directed to nkg2d ligands for the treatment of cancer
Lee et al. Immuno-PET imaging and radioimmunotherapy of lymphomas
ES2880682T3 (es) Anticuerpos anti PSA (5A10) humanizados
CA2723323A1 (en) Use of a radioactively labelled molecule specifically binding to ed-b fibronectin in a method of treatment of hodgkin lymphoma
Kondo HER2-targeted Theranostic Radioimmunoconjugates for SPECT Imaging and α-particle Radioimmunotherapy of HER2-positive Breast Cancer
WO2025160129A1 (en) Methods of use of agents targeting mesenchymal stem cell- derived tumors and tumor associated cells
Sharma et al. A Gallium-68-Labeled Peptide Radiotracer For CD38-Targeted Imaging In Multiple Myeloma With PET
KR20250147080A (ko) 방사성동위원소가 표지된 항-her2 항체-킬레이터 접합체, 이를 포함하는 약학적 조성물 및 이의 제조방법
JP2026501564A (ja) 抗ｒｏｒ－２抗体及びその使用方法
RYAN Bevacizumab radioimmunotherapy (RIT) with accelerated blood clearance using the avidin chase
Oudoux et al. Therapy of medullary thyroid cancer Kraeber-Bodéré
Salouti et al. Breast Cancer: Radioimmunoscintigraphy and Radioimmunotherapy
MOROZ PRECLINICAL TESTING OF NEW MODALITIES FOR PET VISUALIZATION AND TREATMENT OF RAS-DRIVEN CANCERS
HK1258674B (en) Humanized anti psa (5a10) antibodies

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240329

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240329

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250508

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250806

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251007

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251107

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260303